Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Primary angioplasty versus post-fibrinolysis angioplasty in ST-elevation myocardial infarction
2009-012596-94Phase 4Completed
- Sponsor
- Fundación Investigación Biomédica Hospital General Universitario Gregorio Marañón
- Start
- Feb 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tenecteplase and enoxaparin in acute ST-segment elevation myocardial infarction (STEMI) (2 arms), sponsored by Fundación Investigación Biomédica Hospital General Universitario Gregorio Marañón. Primary endpoint: Primary composite clinical efficacy at 12 months. Started Feb 2010; status: completed.
02
Drugs
tenecteplaseenoxaparin
03
Conditions
acute ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on 2009-012596-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012596-94.